Phase II study of antineoplastons A10 and AS2-1 in patients with adenocarcinoma of the pancreas
Phase of Trial: Phase II
Latest Information Update: 23 Nov 2017
At a glance
- Drugs Antineoplaston A10/antineoplaston AS2-1 (Primary)
- Indications Pancreatic cancer
- Focus Therapeutic Use
- 19 Nov 2017 Status changed from active, no longer recruiting to discontinued.
- 18 Apr 2008 Status change from recruiting to in progress, according to clinicaltrials.gov.
- 08 Aug 2005 New trial record.